Pub­li­cis Health snaps up R&D mar­ket­ing group track­ing re­al-world clin­i­cal tri­als – and pa­tient sen­ti­ment

As biotechs move to adopt phar­ma-style mar­ket­ing, Pub­li­cis Health is buy­ing a biotech mar­ket­ing and clin­i­cal tri­al en­roll­ment com­pa­ny. Its pur­chase of BBK World­wide adds re­al-world clin­i­cal tri­al da­ta but al­so pa­tient sen­ti­ment, along with tech­nol­o­gy to ad­vance the small­er com­pa­ny’s “high touch high tech” ap­proach in clin­i­cal tri­al en­gage­ment.

Pub­li­cis Health’s move fol­lows changes in phar­ma and biotech mar­ket­ing as Big Phar­ma de­mands more da­ta and mar­ket­ing plans from biotechs be­fore po­ten­tial ac­qui­si­tions, while more small­er biotechs are tak­ing drugs to mar­ket on their own.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER